In a recent News Generation podcast, Michael Weiner, M.D, a University of California, San Francisco researcher and world-renowned Alzheimer’s expert, discusses use of biomarkers for diagnosis of the disease. Dr. Weiner, Principal Investigator for the Alzheimer's Disease Neuroimaging Initiative (ADNI), explains that before biomarkers for Alzheimer's were identified, clinicians had to rely on signs and symptoms in order to make a diagnosis.
ADNI, the largest-ever Alzheimer's clinical study, is now seeking volunteers for a new phase of the study, which will focus on progression of the disease. DSFederal CEO Sophia Parker praises NIH's efforts, noting that few private corporations now fund or participate in Alzheimer's research projects, leaving most of the burden on NIH. As Nancy Praskievicz explains, DSFederal supports NIH's Alzheimer's research, through our work on the RCDC program, where our team curates the Alzheimer's Disease and Related Dementias reporting categories that are released to the public, helping Congress and citizens understand how NIH is working to study and combat the disease and its related dementias.
Sophia writes: "This is why we're in business, I've seen what this disease does to patients and families, and I'm very proud of our service to the effort to find a cure and end the suffering." Through research support, IT and software development, and process improvement, DSFederal works to develop--and contribute to--transformative solutions that improve human life.